Pronethalol
|  | |
| Systematic (IUPAC) name | |
|---|---|
| 1-(naphthalen-2-yl)-2-(propan-2-ylamino)ethanol | |
| Clinical data | |
| Legal status | 
 | 
| Routes of administration | Oral | 
| Identifiers | |
| CAS Number | 51-02-5 | 
| ATC code | None | 
| PubChem | CID 4930 | 
| ChemSpider | 4761 | 
| UNII | XBP4RT1IMQ | 
| ChEMBL | CHEMBL16476 | 
| Chemical data | |
| Formula | C15H19NO | 
| Molar mass | 229.32 g/mol | 
| Chirality | Racemic mixture | 
| 
 | |
Pronethalol (Alderlin, Nethalide) was an early non-selective beta blocker clinical candidate. It was never used clinically due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite.[1]
See also
References
| 
 | ||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.